These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29397532)

  • 21. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.
    Linjawi S; Bode BW; Chaykin LB; Courrèges JP; Handelsman Y; Lehmann LM; Mishra A; Simpson RW
    Diabetes Ther; 2017 Feb; 8(1):101-114. PubMed ID: 27943107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
    Buse JB; Drucker DJ; Taylor KL; Kim T; Walsh B; Hu H; Wilhelm K; Trautmann M; Shen LZ; Porter LE;
    Diabetes Care; 2010 Jun; 33(6):1255-61. PubMed ID: 20215461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
    Miller LA; Burudpakdee C; Zagar A; Bhosle M; Reaney M; Schabert VF; Bruhn D
    J Med Econ; 2012; 15(4):746-57. PubMed ID: 22443463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
    Wang B; Roth JA; Nguyen H; Felber E; Furnback W; Garrison LP
    PLoS One; 2015; 10(4):e0121915. PubMed ID: 25849542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.
    Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
    Diabetes Ther; 2017 Apr; 8(2):335-353. PubMed ID: 28236271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
    Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH
    Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives.
    Deng W; Qiu S; Yang G; Chen B
    Ther Clin Risk Manag; 2015; 11():1153-62. PubMed ID: 26309403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus.
    Seewoodhary J; Griffin L; Bain SC
    Diabetes Metab Syndr Obes; 2010 May; 3():165-72. PubMed ID: 21437086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study.
    Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
    Diabetes Ther; 2017 Apr; 8(2):321-334. PubMed ID: 28155131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
    Meece J
    Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
    Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.
    Divino V; DeKoven M; Khan FA; Boye KS; Sapin H; Norrbacka K
    Diabetes Ther; 2017 Feb; 8(1):115-128. PubMed ID: 28070733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method.
    Martin AA; Parks D
    Diabetes Metab Syndr Obes; 2016; 9():163-8. PubMed ID: 27274297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting.
    Hu Y; Zheng SL; Ye XL; Shi JN; Zheng XW; Pan HS; Zhang YW; Yang XL; Huang P
    Ann Transl Med; 2022 Feb; 10(3):152. PubMed ID: 35284548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes.
    Aung MM; Slade K; Freeman LAR; Kos K; Whatmore JL; Shore AC; Gooding KM
    Diabetologia; 2019 Sep; 62(9):1701-1711. PubMed ID: 31203378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.
    Montanya E
    Expert Opin Pharmacother; 2012 Jul; 13(10):1451-67. PubMed ID: 22725703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.